|
Match
|
Document |
Document Title |
|
|
US20130160166 |
ORAL INSULIN THERAPY
This disclosure relates in part to synthesizing a cleavable proinsulin construct in transgenic plants by chloroplast expression. |
|
|
US20150133379 |
COSMETIC COMPOSITION FOR IMPROVING SKIN CONDITIONS COMPRISING FUSION PROTEIN
The present invention relates to a fusion protein comprising a skin-penetrating peptide, a polynucleotide encoding the fusion protein, an expression vector comprising the polynucleotide, a... |
|
|
US20110213132 |
PRODUCTION OF NGF IN PLANT
The invention relates to genetically modified plants capable of producing a human recombinant protein Nerve Growth Factor, either in the form of pre-pro-protein or in the mature form and parts and... |
|
|
US20110178275 |
INDUSTRIAL PLANT-BASED PRODUCTION OF ANIMAL-FREE RECOMBINANT PROTEINS IN DEFINED ENVIRONMENT
The present invention provides improved methods for animal-free protein production of high-value heterologous proteins produced in plants, plant derived tissue or plant cells. The invention... |
|
|
US20110288001 |
BIOLOGICALLY ACTIVE PROTEINS ACTIVATABLE BY PEPTIDASE
The present invention provides biologically active proteins that are activatable by peptidase exposure, such as dipeptidase exposure. The biologically active protein may be a recombinant version... |
|
|
US20150258178 |
INTRANASAL INSULIN ADMINISTRATION FOR THE PREVENTION OF ANESTHESIA-INDUCED TAU PATHOLOGY/TAUOPATHIES
Intranasal administration of insulin for a predetermined period prior to anesthesia significantly prevented anesthesia-induced tau hyperphosphorylation and cognitive impairment and enhanced brain... |
|
|
US20120064087 |
METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION
Methods are provided for the diagnosis and treatment of patients with increased risk of preeclampsia. The methods involve measuring levels of TGF-β3, receptors of cytokines of the TGfβ family, or... |
|
|
US20110230404 |
Glycoproteins Produced in Plants and Methods of Their Use
Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive... |
|
|
US20110183855 |
SOMATIC HYPERMUTATION SYSTEMS
The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility... |
|
|
US20130216479 |
SITE-SPECIFIC CHEMICAL MODIFICATION OF PROTEINS AT THEIR N-TERMINI, ENABLING THE FORMATION OF HOMOGENEOUS ADDUCTS
Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous... |
|
|
US20150064720 |
BIOMOLECULE-GRAPHENE QUANTUM DOT CONJUGATES AND USE THEREOF
The invention relates to biomolecules conjugated to graphene quantum dots, and in particular, to use of such biomolecule-graphene quantum dot conjugates as fluorophores for imaging applications. |
|
|
US20130216475 |
METHODS AND COMPOSITIONS FOR PROTEIN LABELLING
A modular platform is provided for rapid preparation of various water-soluble prosthetic groups capable to efficiently introduce 18F into proteins with 18F labelling reagents. |
|
|
US20130184208 |
BMP Mutants with Decreased Susceptibility to Noggin
The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to... |
|
|
US20140170064 |
METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING
Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic... |
|
|
US20120301921 |
COMPOSITIONS AND METHODS OF TREATING DISEASE WITH FGFR FUSION PROTEINS
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion... |
|
|
US20120252729 |
PTH-CONTAINING THERAPEUTIC/PROPHYLACTIC AGENT FOR OSTEOPOROSIS, CHARACTERIZED IN THAT PTH IS ADMINISTERED ONCE A WEEK IN A UNIT DOSE OF 100 TO 200 UNITS
A method of treating osteoporosis by PTH that has excellent safety and high efficacy is disclosed, along with a method for inhibiting/preventing bone fractures by PTH that has excellent safety, as... |
|
|
US20130236959 |
FGF-2 HAVING ENHANCED STABILITY
Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins. |
|
|
US20120129766 |
METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods... |
|
|
US20110294731 |
SKIN CREAM
Preferred embodiments of the invention relate to compositions, including anti-aging cosmeceuticals for topical application, and more particularly, a skin cream, comprising cell culture medium... |
|
|
US20130045479 |
METHODS FOR EVALUATING THE STAGE OF OVARIAN CANCER OR THE SURVIVAL RATE OF AN OVARIAN CANCER PATIENT
An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and... |
|
|
US20130331325 |
CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20140107022 |
CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20140094406 |
CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20130331317 |
CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20130331316 |
CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and... |
|
|
US20140322752 |
REFOLDING TRANSFORMING GROWTH FACTOR BETA FAMILY PROTEINS
Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when... |
|
|
US20150166628 |
SELECTIVE CARTILAGE THERAPY
The present invention relates to compositions, methods and kits for delivery of an IGF-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express... |
|
|
US20140142038 |
ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING
The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical... |
|
|
US20120165245 |
ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING
The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical... |
|
|
US20120244577 |
MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS
Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at... |
|
|
US20110039775 |
THYROID STIMULATING HORMONE FUSION PROTEINS
We disclose TSH fusion proteins comprising TSHα and/or TSH β and methods to treat diseases that would benefit from administration of TSH agonists and antagonists. |
|
|
US20120258519 |
Protein Harvesting
Methods of harvesting proteins directly from bioreactors to avoid at several steps in the purification of recombinant drugs are disclosed. |
|
|
US20110166067 |
METHODS FOR INHIBITION OF SCARRING
The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment... |
|
|
US20140087998 |
USE OF PACAP FOR THE TREATMENT VIRAL INFECTIONS IN AQUATIC ORGANISMS
The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic... |
|
|
US20140213776 |
METHODS AND COMPOSITIONS COMPRISING HUMAN RECOMBINANT GROWTH AND DIFFERENTIATON FACTOR-5 (RHGDF-5)
Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high... |
|
|
US20140212952 |
METHODS AND COMPOSITIONS OF HUMAN RECOMBINANT GROWTH AND DIFFERENTIATON FACTOR-5 (RHGDF-5) ISOLATED FROM INCLUSION BODIES
Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high... |
|
|
US20130012684 |
Purification Method
The present invention provides a method for purification of a protein that is conjugated to an albumin binding moiety from a mixture comprising (i) said protein in said conjugated form and (ii)... |
|
|
US20120174264 |
Uses of Yerba Santa
Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium.... |
|
|
US20110059501 |
Protein Glycosylation
The present invention relates to methods for glycosylating a protein in which the protein is modified to include an alkyne and/or an azide group. The invention further relates to a protein... |
|
|
US20130130967 |
Method for Uses of Protein Precursors as Prodrugs
The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein... |
|
|
US20120258917 |
Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β... |
|
|
US20120040900 |
COMPOSITIONS OF AND METHODS OF USING LIGAND DIMERS
Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force... |
|
|
US20130184209 |
PROTEIN STABILIZATION FORMULATIONS
The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including... |
|
|
US20110237506 |
PROTEIN STABILIZATION FORMULATIONS
The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including... |
|
|
US20140206611 |
LONG-ACTING INSULIN FORMULATIONS
The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. |
|
|
US20120202263 |
Bioactive Macromers and Hydrogels and Methods for Producing Same
The invention concerns macromers, having a molecular weight of at least 2 kDa, comprising at least one unit of the formula P-(protein-P)n, wherein: P is selected from polyethylene glycol (PEG),... |
|
|
US20080227960 |
Crystal structure of estrogen receptor-beta complex and uses thereof
This invention is directed to the crystal structure of Estrogen Receptor-β (ER-β) complexed with genistein, and to the use of this structure in rational drug design methods to identify agents that... |
|
|
US20150157735 |
PROTOZOAN VARIANT-SPECIFIC SURFACE PROTEINS (VSP) AS CARRIERS FOR ORAL DRUG DELIVERY
The invention provides compositions for oral delivery and methods of treatment using VSP carriers, such as Giardia sp. variable surface proteins (VSP), to deliver therapeutic agents. VSP drug... |
|
|
US20110305770 |
RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM
The present invention relates to polymer conjugated releasable lipids and nanoparticle compositions containing the same for the delivery of nucleic acids and methods of modulating gene expression... |
|
|
US20140336367 |
RECOMBINANT NEL-LIKE (NELL) PROTEIN PRODUCTION
The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide. |